Narrative Review of the Mechanisms and Treatment of Cough in Asthma, Cough Variant Asthma, and Non-asthmatic Eosinophilic Bronchitis

Eosinophilic plastic bronchitis: Case series and review of the literature

“…In our case series, an endobronchial biopsy was performed in three patients and demonstrated eosinophilic inflammation (bronchitis). Non‐asthmatic eosinophilic bronchitis was first described in 1989 and is defined by the presence of chronic cough with sputum eosinophilia (>2.5%) and no airway hyperresponsiveness 22–24 . This condition is effectively treated by ICS.…”

“…Non-asthmatic eosinophilic bronchitis was first described in 1989 and is defined by the presence of chronic cough with sputum eosinophilia (>2.5%) and no airway hyperresponsiveness. [22][23][24] This condition is effectively treated by ICS. Bronchial cast formation has not been described in association with eosinophilic bronchitis and although it is likely a different condition than eosinophilic plastic bronchitis, the underlying pathophysiology may be similar in at least a subset of patients.…”

Herb-CMap: Novel Hot Diffusion Algorithm to Identify Bioactive Ingredients from Herbal Medicine Based on Gene Perturbation Profiling

“…Cough variant asthma (CVA) is a type of asthma with bronchial hyperreactive eosinophilic airway inflammation and airway remodeling. Severe and frequent coughs will damage the respiratory tract and aggravate respiratory infection, which has affected patients’ quality of life and caused a considerable burden to society 22, 23 . CVA has the features of paroxysmal, spasmodic, and repetitive coughs, which corresponds to the “wind cough” syndrome in TCM theory.…”

LUNG Year in Review: 2022

“…Clinical studies of COPD examined diagnosis [ 2 ], risk factors [ 3 ], predictors of outcomes [ 4 – 9 ], and therapeutic interventions [ 10 , 11 ], whereas preclinical investigations evaluated chronic cigarette smoke-induced inflammation and airway remodeling [ 12 , 13 ]. Contributions in the field of asthma included physiological studies [ 14 – 18 ], effects of therapeutic interventions [ 19 ], social determinants of clinical outcomes [ 20 ], asthma-associated cough [ 21 , 22 ] and preclinical investigations [ 23 ].…”

“…Indeed, 2022 witnessed the approval of the first-ever drug indicated for the treatment of refractory chronic cough [ 51 , 52 ]. LUNG continued its emphasis on high-quality cough-related research by featuring numerous articles, including those examining asthma-associated cough [ 21 , 22 ]; cough associated with IPF [ 53 ] and COVID19 [ 54 ]; methodology of objective cough counting [ 55 , 56 ]; cough-related healthcare utilization [ 57 , 58 ]; physiology [ 59 ]; and, studies of potential antitussive drugs [ 60 – 62 ].…”